Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.
about
Clinical utility of lanreotide AutogelĀ® in gastroenteropancreatic neuroendocrine tumorsSystematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumoursChallenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future ConsiderationsNew therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies90Y-edotreotide for metastatic carcinoid refractory to octreotide.Requiem for the term 'carcinoid tumour' in the gastrointestinal tract?LanroNET, a non-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors - results of interim analysis.Safety and efficacy of everolimus in adult patients with neuroendocrine tumors.Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.Results of a prospective multicenter neuroendocrine tumor registry reporting on clinicopathologic characteristics of Greek patients.Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.The expanding role of somatostatin analogs in the management of neuroendocrine tumors.Carcinoid syndrome: diagnosis and medical management.Lanreotide Autogel in the Treatment of Persistent Diarrhea following a Total Colectomy.The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursSomatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real lifeFrom somatostatin to octreotide LAR: evolution of a somatostatin analogueUpdate on management of midgut neuroendocrine tumors.Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreasSomatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives.High-dose lanreotide in the treatment of poorly differentiated pancreatic neuroendocrine carcinoma: a case report.Gastrointestinal neuroendocrine tumors.Liver-specific therapies for metastases of neuroendocrine pancreatic tumorsSafety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors.Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.The use of biomarkers in neuroendocrine tumours.Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.Flushing in (neuro)endocrinology.The safety of available treatments options for neuroendocrine tumors.Population Pharmacokinetic Analysis of Lanreotide Autogel/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials.Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel).Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths
P2860
Q28069632-EC3FF4CF-D79F-4716-A6FD-6D27FD242536Q28071978-8F2F25B3-9BCF-4393-83F0-D382EAE8184FQ28084155-87C3988A-AB6E-4405-B175-FB8C9B239C44Q30364864-86FEE23D-79DC-41DA-9963-6D079D9B28F2Q33753449-9F8C13F8-6587-431E-9933-489DBADF575AQ33840177-3C7E50AE-0CD6-479F-819C-DC6B355A39B6Q34101554-0ECE2E6A-CE0D-4E8B-9CB4-306CB9BCE968Q34770091-967B2D40-61B8-4736-9536-C971AB4F4C54Q35165592-64BDD380-547D-4F8F-9EEC-54F3C3456AEAQ35669138-56133A96-92D2-42D4-AB09-D7B05FC8311EQ35738251-83DB7227-6446-481F-A673-D8C5CF4BCB65Q35837124-172C5248-9413-406B-B796-8B30485A3728Q35922755-957F8601-2F37-4978-A547-7B7590A870ABQ36184629-5A32FC94-9F3D-4A0B-BC36-74A9D4C8613CQ36347272-4469F533-732A-40A6-B8AC-E87481C8AD4EQ36380878-5185BAD6-B78A-44F6-8433-9B54883B8F4EQ36386610-B6783A56-A766-41A5-A368-A1364BE43E64Q36755905-265C28DD-4649-4717-938F-82F3984D5F8CQ36905710-5E860FBC-AEBD-40F5-95E7-19B357DBE577Q36919554-5E528A4E-4204-46FF-BF18-74964BD04D6CQ37025143-CD3CA7E5-C4B7-4FC4-AF9B-FF05F539B8D3Q37402462-1BFE704E-74A0-4F16-931E-D70426CA9BD5Q37564373-256D5145-35B1-4FEF-84BF-4DB87E6396F1Q37684775-8191E43D-CF66-4BEA-973A-F0B1A70912C4Q37799954-CC098255-8FD8-422F-85FB-D15735D74177Q37821300-79726C66-54B5-4E8E-A54A-FCE3737910D8Q37941521-E8B23555-68ED-48F6-AECD-C43236A939A1Q38257060-EEFA2271-0B1F-4A18-B046-827DB51AB2FCQ38609117-47659AE1-6C99-4DE9-A20D-0C2BA6632C64Q38647297-08A494B6-6BDF-4DD1-A47D-DC3689CA1F56Q39016266-BB85794C-3142-45AB-8E8F-06DE030C3355Q39433254-39922157-5B7E-4FC9-88ED-B775DF4400A8Q40489239-44E7EDAC-F4C1-44D8-BFDA-F454D6ECB3DFQ42697290-9C85E18C-ADBF-405E-9A69-28FD8B58D40EQ42744657-9E554037-7436-4C33-8E65-86E0835BB41BQ46141893-1D75BB08-B1DD-49E6-8F32-E165054BCC4AQ46950109-4E6913FF-061D-4DFE-A58C-49A5D3923793Q50059510-FD9BF958-1B5F-428E-9CA4-E96ABAC810B2Q56962802-865A2266-2B80-4E19-9F15-AE69FB95FA59
P2860
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.
description
2004 nĆ® lÅ«n-bĆ»n
@nan
2004幓ć®č«ę
@ja
2004幓å¦ęÆęē«
@wuu
2004幓å¦ęÆęē«
@zh-cn
2004幓å¦ęÆęē«
@zh-hans
2004幓å¦ęÆęē«
@zh-my
2004幓å¦ęÆęē«
@zh-sg
2004幓åøč”ęē«
@yue
2004幓åøč”ęē«
@zh
2004幓åøč”ęē«
@zh-hant
name
Rapid and sustained relief fro ...... ase formulation of lanreotide.
@en
Rapid and sustained relief fro ...... ase formulation of lanreotide.
@nl
type
label
Rapid and sustained relief fro ...... ase formulation of lanreotide.
@en
Rapid and sustained relief fro ...... ase formulation of lanreotide.
@nl
prefLabel
Rapid and sustained relief fro ...... ase formulation of lanreotide.
@en
Rapid and sustained relief fro ...... ase formulation of lanreotide.
@nl
P2093
P2860
P50
P356
P1433
P1476
Rapid and sustained relief fro ...... ase formulation of lanreotide.
@en
P2093
Ashley Grossman
Barbro Eriksson
Benjamin Glaser
Catherine Lombard-Bohas
Dermot O'Toole
Eric Van Cutsem
Gianfranco Delle Fave
Jean FranƧois Seitz
Machteld Wymenga
Martyn Caplin
P2860
P304
P356
10.1159/000082875
P577
2004-12-22T00:00:00Z